121 related articles for article (PubMed ID: 36005823)
1. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Nov; 27(11):e917-e918. PubMed ID: 36005823
[TBL] [Abstract][Full Text] [Related]
2. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?
Saad Albichr I; De Greef J; Van Den Neste E; Poiré X; Havelange V; Vekemans MC; Bailly S; Yombi JC; Mzougui S; Scohy A; Kabamba-Mukadi B
Leuk Lymphoma; 2022 Mar; 63(3):743-746. PubMed ID: 34706604
[No Abstract] [Full Text] [Related]
3. Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination.
Sriwijitalai W; Wiwanitkit V
Oncologist; 2022 Nov; 27(11):e916. PubMed ID: 36018054
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.
Wang L; Wang W; Xu R; Berger NA
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101384. PubMed ID: 36494154
[TBL] [Abstract][Full Text] [Related]
5. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
6. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
Kamboj M
Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
[No Abstract] [Full Text] [Related]
7. COVID-19 vaccines for patients with haematological conditions.
Sun C; Pleyer C; Wiestner A
Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
[No Abstract] [Full Text] [Related]
8. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.
Ni B; Yanis A; Dee K; Chappell JD; Dulek DE; Kassim AA; Kitko CL; Thomas LD; Halasa N
Blood Rev; 2022 Nov; 56():100984. PubMed ID: 35752546
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in patients with hematologic malignancy.
Langerbeins P; Hallek M
Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 vaccine efficacy in a rapidly changing landscape.
Baer SL; Tran S
J Investig Med; 2022 Aug; 70(6):1327-1328. PubMed ID: 35768142
[No Abstract] [Full Text] [Related]
11. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
12. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Cook LB; O'Dell G; Vourvou E; Palanicawandar R; Marks S; Milojkovic D; Apperley JF; Loaiza S; Claudiani S; Bua M; Hockings C; Macdonald D; Chaidos A; Pavlu J; Cooper N; Fidler S; Randell P; Innes AJ
Nat Commun; 2022 Nov; 13(1):6922. PubMed ID: 36376307
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccine response in patients with hematologic malignancy: A systematic review and meta-analysis.
Gong IY; Vijenthira A; Betschel SD; Hicks LK; Cheung MC
Am J Hematol; 2022 Apr; 97(4):E132-E135. PubMed ID: 35007350
[No Abstract] [Full Text] [Related]
14. High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination.
Shapiro LC; Thakkar A; Gali R; Gonzalez-Lugo JD; Bazarbachi AH; Rahman S; Pradhan K; Fehn K; Abreu M; Kornblum N; Gritsman K; Goldfinger M; Shastri A; Mantzaris I; Braunschweig I; Halmos B; Verma A; McCort M; Bachier-Rodriguez L; Sica RA
Leuk Lymphoma; 2022 Oct; 63(10):2484-2488. PubMed ID: 35593019
[No Abstract] [Full Text] [Related]
15. COVID-19 vaccine effectiveness in patients with hematologic malignancy.
Shah DP; Shah PK; Thompson MA
Transpl Infect Dis; 2022 Dec; 24(6):e13850. PubMed ID: 35584967
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 Vaccine Effectiveness in Youth Varies by Age, Variant.
Kuehn BM
JAMA; 2022 Apr; 327(16):1540. PubMed ID: 35471503
[No Abstract] [Full Text] [Related]
17. Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study.
Rooney A; Bivona C; Liu B; Streeter D; Gong H; Khan Q
J Hematol Oncol; 2022 May; 15(1):67. PubMed ID: 35597960
[TBL] [Abstract][Full Text] [Related]
18. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies.
Greenberger LM; Saltzman LA; Senefeld JW; Johnson PW; DeGennaro LJ; Nichols GL
Cancer Cell; 2021 Aug; 39(8):1031-1033. PubMed ID: 34331856
[No Abstract] [Full Text] [Related]
19. Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination.
Callegari C; Lazzarotto D; Soravia A; Mutti M; Lauzzana P; Peghin M; Cordella S; Fanin R; Candoni A
Eur J Haematol; 2023 Oct; 111(4):668-670. PubMed ID: 37461815
[No Abstract] [Full Text] [Related]
20. Cancer Therapy Doesn't Diminish Vaccine Efficacy.
Cancer Discov; 2021 Dec; 11(12):OF1. PubMed ID: 34620689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
